A regimen based on the combination of trimethoprim/sulfamethoxazole with caspofungin and corticosteroids as a first-line therapy for patients with severe non-HIV-related pneumocystis jirovecii pneumonia: a retrospective study in a tertiary hospital.

"Declarations Ethical approval and consent to participateEthical approval was obtained from the Ethics Review Board of the First Affiliated Hospital of Xi’an Jiaotong University (No. XJTU1AF2019LSL-016). All methods were performed in accordance with relevant guidelines and regulations by the Ethics Review Board of the First Affiliated Hospital of Xi’an Jiaotong University. Informed consent was obtained from all the participants and/or their legal guardians. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding This study was supported by the National Nature Science Foundation of China (No. 82070549 (H. L.), No. 81460287 (QDS) and No. 81600327 (YW)); the Natural Science Basic Research Plan in Shaanxi Province (No. 2022JM-477 (H. L.)); the Dr. Li Jieshou. (Academician of CAS) Research Fund for Intestinal Barrier (No. LJS-201801 A (H. L.)); the clinical research award of the First Affiliated Hospital of Xi’an Jiaotong University (grant/award number: XJTU1AF-CRF-2019-016); and the Key R&D Projects in Shaanxi Province (grant no. 2020ZDLFY08-04). We thank the Biobank of the First Affiliated Hospital of Xi’an Jiaotong University for providing clinical data."